Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

SIOX - Sio Gene Therapies Inc


Previous close
0.478
0   0%

Share volume: 40,403
Last Updated: Wed 07 Feb 2024 06:00:00 AM CET
Pharmaceutical Preparation Manufacturing : -2.88%

PREVIOUS CLOSE
CHG
CHG%

$0.48
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
57%
Profitability 68%
Dept financing 0%
Liquidity 0%
Performance 75%
Performance
5 Days
22.88%
1 Month
24.16%
3 Months
22.60%
6 Months
23.16%
1 Year
18.76%
2 Year
18.76%
Key data
Stock price
$0.48
P/E Ratio 
0.00
DAY RANGE
$0.48 - $0.48
EPS 
$0.00
52 WEEK RANGE
$0.25 - $0.50
52 WEEK CHANGE
$0.19
MARKET CAP 
35.360 M
YIELD 
N/A
SHARES OUTSTANDING 
73.975 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$288,520
AVERAGE 30 VOLUME 
$130,029
Company detail
CEO: Pavan Cheruvu
Region: US
Website: http://www.axovant.com/
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

axovant develops transformative gene therapies for patients with life-altering neurologic conditions. our mission is to identify, develop, and bring to market high-impact therapies that have the potential to improve the lives of patients with neurological disorders. our team is made up of leading scientific experts who are passionate about treating neurological conditions and easing the burden of these life-changing disorders for both patients and caregivers. our team is motivated by the promise of novel drug development, and is driven to find more efficient and effective ways to conduct scientific and clinical evaluations that rapidly deliver impactful medicines to patients in need. our leadership team has a track record bringing innovative new neurotherapeutic treatments to a global market, and along with our seasoned board of directors, is fully committed to the responsible pursuit of transformative therapies for some of the world's most difficult conditions.

Recent news